Apollo Cancer Centre Launches India’s First LungLife Screening Programme

Apollo Cancer Centres (ACCs) has introduced India’s first LungLife Screening Programme to aid in the early detection of lung cancer. This revolutionary initiative seeks to tackle lung cancer, which accounts for 5.9 per cent of all cancers and 8.1 per cent of cancer-related deaths in India. By focusing on early detection, the programme aims to improve treatment outcomes and significantly enhance survival rates.

According to GLOBOCAN 2020 estimates produced by the International Agency for Research on Cancer (IARC), lung cancer remains the leading cause of cancer deaths worldwide, with 1.8 million fatalities (18 per cent) reported in 2020.

The LungLife Screening Programme is targeted at high-risk individuals, including those aged between 50 and 80 years, individuals with no symptoms of lung cancer, those with a history of smoking, and people with a family history of lung cancer. Early screening through low-dose computed tomography (LDCT) is emphasised as a vital diagnostic tool, as it not only ensures early detection but also significantly boosts survival rates. However, studies reveal that approximately 80 per cent of high-risk individuals have never discussed screening options with healthcare providers. The initiative, therefore, underscores the importance of creating awareness and improving communication around lung cancer screening to save lives.

Harshad, Director – Group Oncology & International, Apollo Hospitals, described the programme as a landmark initiative in the hospital’s ongoing efforts to advance oncology care in India. “The LungLife Screening Programme is a testament to our commitment to providing individuals with resources and knowledge to proactively safeguard their health. Apollo Cancer Centres is steadfast in its mission to elevate cancer care standards and drive nationwide collaboration in the fight against lung cancer,” he said.

Dr Sridhar Ravichandran, Consultant Pulmonologist at Apollo Proton Cancer Centre, highlighted the deadly nature of lung cancer but stressed the benefits of early detection. “Using advanced low-dose CT technology, we aim to identify high-risk individuals early, reducing radiation exposure while maximising diagnostic precision. This programme brings renewed hope for better treatment outcomes, particularly for those with smoking histories or genetic predispositions,” he explained.

Dr P.B. Vandana, Pulmonary Medicine Specialist at Apollo Specialty Hospitals, Vanagaram, described the programme as a pivotal step towards addressing the growing burden of lung cancer in India. “Early-stage detection exponentially increases the chances of effective treatment and recovery. The LungLife Screening Programme combines state-of-the-art diagnostic tools with patient safety to ensure accurate and timely interventions,” she said.

Adding to these sentiments, Dr Jebin Roger S, Consultant Pulmonologist at Apollo Cancer Centre, Teynampet, noted the critical role of early detection in improving survival rates. “Lung cancer is often a silent threat, diagnosed only at advanced stages. With this initiative, Apollo is revolutionising lung cancer care by combining precision diagnostics with a patient-centred approach,” he said.